Heron Therapeutics (HRTX) Stock Forecast: StockMap's 2-Week Call

HRTX stock forecast: StockMap's model leans Underperform on Heron Therapeutics for the two weeks after the Nov 19 close, toward HRTX trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 2 of 6 two-week windows on HRTX since Aug 21; by chance, a call on the same dates was right 58% of the time.

Heron Therapeutics last closed at $0.26, -3.70% on the session.

Against the IVW growth benchmark the position is -1.37% over the forecast window.

Heron Therapeutics' market cap is $50.02M as of November 19, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -27 (too close to call).

Where HRTX sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

44 daily calls for HRTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Heron Therapeutics in the 2nd percentile on return on equity, where 100 is best.

Heron Therapeutics is classified under Health Care / Biotechnology.

StockMap tracks Heron Therapeutics as the 308th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.

On that composite Heron Therapeutics ranks 209th of 394 in the group, against a group median of -0.27.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Heron Therapeutics (HRTX) — StockMap 2-week forecast & tracked accuracy